Document is current
Any future updates will be listed below
-
Authors
McLaughlin, N. C. R.
Magnotti, J. F. https://orcid.org/0000-0003-2093-0603
Banks, G. P.
Nanda, P.
Hoexter, M. Q.
Lopes, A. C.
Batistuzzo, M. C. https://orcid.org/0000-0003-1347-8241
Asaad, W. F.
Stewart, C.
Paulo, D.
Noren, G.
Greenberg, B. D.
Malloy, P.
Salloway, S.
Correia, S.
Pathak, Y.
Sheehan, J.
Marsland, R.
Gorgulho, A.
De Salles, A.
Miguel, E. C. https://orcid.org/0000-0002-9393-3103
Rasmussen, S. A.
Sheth, S. A.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (5K23MH100607)
- License Information
-
More Information
Article History
Received: 14 March 2022
Revised: 27 February 2023
Accepted: 31 March 2023
First Online: 26 April 2023
Conflict of interest
: This work was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP, State of São Paulo Research Foundation grants 2011/21357-9, 2013/16864-4, and 2014/50917-0). NCRM has received research support from the NIH (5K23MH100607) and the National Institute of General Medical Sciences (5P20GM130452). SAS acknowledges support from the McNair Foundation and Dana Foundation and is a consultant for Boston Scientific, Zimmer Biomet, Abbott, and Neuropace. SS has no relevant disclosures related to the current work. He receives research support for the conduct of clinical trials from Lilly, Biogen, Genentech, Avid, Roche, Eisai, and Novartis. He was a site PI for the PRIME, ENGAGE, Clarity, and Trailblazer 1 trials. He is a co-chair of the investigator steering committee for the aducanumab phase 3 program and he is the Project Arm Leader for gantenerumab in the DIAN-TU study. He is a consultant to Lilly, Biogen, Roche, Genentech, Eisai, Bolden, Amylyx, NovoNordisk, Prothena, Ono and Alnylam. He owns no stocks or equity in any pharmaceutical company and has no patents or royalties. BDG has received research funding from the Dana Foundation, and research funding from Neurolief, Inc. WFA has research support through the Medtronic External Research Program, and is a site PI for multi-site clinical trials supported by Functional Neuromodulation Inc., Vivonics Inc. and Biogen Inc. All other authors report no competing interests.
